EMA/PE/0000182225
Submitted by Anonymous (not verified) on 3 July 2026 - 15:58
EMA/PE/0000182225
EMA/PE/0000237903
Submitted by Anonymous (not verified) on 3 July 2026 - 15:55
EMA/PE/0000237903
EMA/PE/0000239753
Submitted by Anonymous (not verified) on 3 July 2026 - 15:52
EMA/PE/0000239753
Human medicines European public assessment report (EPAR): Redemplo, plozasiran, Date of authorisation: 19/06/2026, Status: Authorised
Submitted by Anonymous (not verified) on 3 July 2026 - 15:50
Human medicines European public assessment report (EPAR): Redemplo, plozasiran, Date of authorisation: 19/06/2026, Status: Authorised
Human medicines European public assessment report (EPAR): Retsevmo, selpercatinib, Date of authorisation: 11/02/2021, Revision: 21, Status: Authorised
Submitted by Anonymous (not verified) on 3 July 2026 - 15:36
Human medicines European public assessment report (EPAR): Retsevmo, selpercatinib, Date of authorisation: 11/02/2021, Revision: 21, Status: Authorised
Human medicines European public assessment report (EPAR): Pyzchiva, ustekinumab, Date of authorisation: 19/04/2024, Revision: 15, Status: Authorised
Submitted by Anonymous (not verified) on 3 July 2026 - 15:30
Human medicines European public assessment report (EPAR): Pyzchiva, ustekinumab, Date of authorisation: 19/04/2024, Revision: 15, Status: Authorised
Human medicines European public assessment report (EPAR): Opuviz, aflibercept, Date of authorisation: 13/11/2024, Revision: 4, Status: Authorised
Submitted by Anonymous (not verified) on 3 July 2026 - 15:26
Human medicines European public assessment report (EPAR): Opuviz, aflibercept, Date of authorisation: 13/11/2024, Revision: 4, Status: Authorised
Human medicines European public assessment report (EPAR): Cejemly, sugemalimab, Date of authorisation: 24/07/2024, Revision: 7, Status: Authorised
Submitted by Anonymous (not verified) on 3 July 2026 - 15:25
Human medicines European public assessment report (EPAR): Cejemly, sugemalimab, Date of authorisation: 24/07/2024, Revision: 7, Status: Authorised
Human medicines European public assessment report (EPAR): Kesimpta, ofatumumab, Date of authorisation: 26/03/2021, Revision: 15, Status: Authorised
Submitted by Anonymous (not verified) on 3 July 2026 - 15:00
Human medicines European public assessment report (EPAR): Kesimpta, ofatumumab, Date of authorisation: 26/03/2021, Revision: 15, Status: Authorised
Human medicines European public assessment report (EPAR): Lorviqua, lorlatinib, Date of authorisation: 06/05/2019, Revision: 17, Status: Authorised
Submitted by Anonymous (not verified) on 3 July 2026 - 14:50
Human medicines European public assessment report (EPAR): Lorviqua, lorlatinib, Date of authorisation: 06/05/2019, Revision: 17, Status: Authorised